Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.53 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16712642 | 0.92 | HRH3 (0.55) | HRH3ACHE | |
| SCHEMBL16702266 | 0.84 | DRD2 (0.61) | HRH3DRD2HTR1AHTR2ASLC6A4 | |
| SCHEMBL16704219 | 0.81 | MAOB (0.43) | HRH3DRD2HTR1AACHE | |
| SCHEMBL16702159 | 0.79 | MAOA (0.41) | HRH3DRD2HTR1A | |
| SCHEMBL16702070 | 0.76 | HRH3 (0.45) | HRH3DRD2HTR1ADDB1CRBN | |
| SCHEMBL16703990 | 0.76 | MAOA (0.39) | HRH3DRD2HTR1ASLC6A4 | |
| SCHEMBL16701948 | 0.76 | HRH3 (0.40) | HRH3DRD2HTR1A | |
| SCHEMBL16712643 | 0.76 | DRD2 (0.62) | HRH3DRD2HTR1AACHESLC6A4 | |
| SCHEMBL16701815 | 0.72 | GPR119 (0.43) | DRD2HTR1A | |
| SCHEMBL16702375 | 0.72 | HTR1A (0.39) | DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015069110-A1 | MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS | AAPA B.V. (NL) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015069110-A1 | MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS | AAPA B.V. (NL) | 2015-05-14 | — | — | WO | disclosed |